Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
04/2007
04/26/2007US20070093553 HMB compositions and uses thereof
04/26/2007US20070093552 Early insulin secretion stimulator
04/26/2007US20070093551 Hydroxy-oligocarboxylic esters: effects on nerve and use for cutaneous and mucocutaneous organs or sites
04/26/2007US20070093550 Method and compound for the prophylaxis or treatment of an immunodeficiency condition, such as AIDS
04/26/2007US20070093549 Methods for preparation of ladostigil tartrate crystalline form A1
04/26/2007US20070093548 Use of progesterone receptor modulators
04/26/2007US20070093547 Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
04/26/2007US20070093546 Use of rotigotine for the treatment of depression
04/26/2007US20070093545 4-Oxo-4,5-dihydro-furan-2-carboxylic acid derivatives and methods of treatment of metabolic-related disorders thereof
04/26/2007US20070093544 1-((4-Tert-butylcyclohexyl)(1-methyl-5-propoxy-1H-benzimidazol-2-yl-amino-)-N-1H-tetrazole-5-yl-indane-5-carboxamide; glucagon receptor antagonists; antidiabetic agents; type 2 diabetes mellitus; insulin resistance; gluconeogenesis inhibitors; lowering rate of hepatic glucose output; hypoglycemic agents
04/26/2007US20070093542 Process for the preparation of valsartan and intermediates thereof
04/26/2007US20070093541 Treatment of dementia and/or regression of cognitive function, by coadministration of an ANG II antagonist such as telmisartan and an ACE inhibitor such as ramipril
04/26/2007US20070093540 process for the preparation of angiotensin ii antagonistic compounds
04/26/2007US20070093539 N-hydroxy-4-(3-pheyl-5-methyl-isoxazole-4-yl)-benzenesulfonate solvates
04/26/2007US20070093537 Thiazolyl-based compounds useful as kinase inhibitors
04/26/2007US20070093536 Target protein of antidiabetic and novel antidiabetic insuful corresponding thereto
04/26/2007US20070093535 Vinyl phenyl derivatives as GLK activators
04/26/2007US20070093534 Modulation of Pathogenicity
04/26/2007US20070093533 Crystalline S-omeprazole strontium hydrate, method for preparing same, and pharmaceutical composition containing same
04/26/2007US20070093532 Benzimidazole carboxamides as raf kinase inhibitors
04/26/2007US20070093531 Novel hydroxyindoles, their use as inhibitors of phosphodiesterase 4, and processes for preparing them
04/26/2007US20070093530 Substituted indolealkanoic acids
04/26/2007US20070093529 Diacylhydrazine derivatives
04/26/2007US20070093528 Pyridyltetrahydropyridines and pyridylpiperidines and method of manufacturing them
04/26/2007US20070093527 Methods for treating disorders associated with hyperlipidemia in a mammal
04/26/2007US20070093526 4-Amino-piperidine derivatives as monoamine uptake inhibitors
04/26/2007US20070093525 Microsomal triglyceride transfer protein (MTP) inhibitor (S)-2-[(4'-Isopropoxybiphenyl-2-carbonyl)amino]quinoline-6-carboxylic acid {[(4-fluoro-benzyl)methylcarbamoyl]phenylmethyl}amide; treating obesity
04/26/2007US20070093524 5-Lipoxygenase modulators
04/26/2007US20070093523 Tetrahydroisoquinoline LXR modulators
04/26/2007US20070093522 To treat pain, drug addiction, or tinnitus; selectively inhibit sodium or calcium ion channels and agonize or antagonize mu -opioid receptors; N-Benzyl-N-(2-dimethylamino-ethyl)-2-(S)-[3-(4-fluorophenyl)-ureido]-3-methyl-butyramide
04/26/2007US20070093521 Benzooxazole, oxazolopyridine, benzothiazole and thiazolopyridine derivatives
04/26/2007US20070093520 Method of treatment of diarrhea-predominant irritable bowel syndrome in a subject
04/26/2007US20070093519 Anti-emetic uses of cannabinoid analogs
04/26/2007US20070093518 Pharmaceutical compositions for the treatment of organophosphate poisoning
04/26/2007US20070093517 Local anesthetic compositions
04/26/2007US20070093516 reducing blood glucose levels, weight gain, non-insulin dependent diabetes, obesity or metabolic syndrome in mammals comprising administering pyrimidin-2-one's such as 5-(4-hydroxyphenoxy)-1H-pyrimidin-2-one and optionally rosiglitazone,
04/26/2007US20070093515 Phosphodiesterase 10 inhibitors
04/26/2007US20070093514 Use of 5-[4-[[3-methyl-4-oxo-3,4-dihydro-2-quinazolinyl]methoxy]phenylmethyl]thiazolidine-2,4-dione or N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine; dry eyes, corneal ulcer, keratitis, conjunctivitis
04/26/2007US20070093513 Agent for repairing corneal perception
04/26/2007US20070093512 4-Phenylaminopyrido[4,3-d]pyrimidines 6-heteroaryl-substituted, in which the heteroaryl is substituted with a sulfonylethylamino-, thio- or oxy- group; protein tyrosine kinase inhibitors, used especially to treat various malignancies
04/26/2007US20070093511 Anhydrous Crystal Form of Valaciclovir Hydrochloride
04/26/2007US20070093510 Phosphodiesterase 4 inhibitors
04/26/2007US20070093509 Non-basic melanin concentrating hormone receptor-1 antagonists
04/26/2007US20070093508 Non-basic melanin concentrating hormone receptor-1 antagonists
04/26/2007US20070093507 Compositions comprising benzo (g) quinoline derivatives and prostaglandin derivatives
04/26/2007US20070093506 Inhibitors of tyrosine kinases
04/26/2007US20070093505 2,3-Substituted 5,6-diaryl-pyrazine derivatives as cb1 modulators
04/26/2007US20070093504 Salts of Modulators Of PPAR and Methods of Treating Metabolic Disorders
04/26/2007US20070093503 Methods and kit for treating parkinson's disease
04/26/2007US20070093502 5- Or 6-substituted benzimidazole derivatives as inhibitors of respiratory syncytial virus replication
04/26/2007US20070093501 Urea derivative, process for producing the same, and use
04/26/2007US20070093500 adrenoreceptor modulators for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms; 4,5,6,7-tetrafluoro-2-{4-[4-(2-isopropoxy-phenyl)-piperazin-1-yl]-cyclohexyl}-isoindole-1,3-dione
04/26/2007US20070093499 Use of dasatinib for the treatment of bone metastasis
04/26/2007US20070093498 Thieno-pyrimidine compounds having fungicidal activity
04/26/2007US20070093497 Methotrexate compliance packaging
04/26/2007US20070093496 Hydroxy pyridopyrrolopyrazine dione compounds useful as hiv integrase inhibitors
04/26/2007US20070093495 Methods for treatment of parkinson's disease
04/26/2007US20070093494 e.g. 8-(5-bromoquinoxalin-6-yl)-5-oxo-2,3,5,6,7,8-hexahydroimidazo[1,2-a]pyrimidine-7-carboxylic acid; beta -adrenoreceptor antagonists; ocular hypotensive agents; glaucoma
04/26/2007US20070093493 Treatment of benign prostatic hypertrophy and lower urinary tract symptoms
04/26/2007US20070093492 Pyrrolidine derivatives
04/26/2007US20070093491 Novel condensed n-pyrazinyl-sulphonamides and their use in the treament of chemokine mediated diseases
04/26/2007US20070093490 protein kinase inhibitors such as (3-phenylimidazo[1,2b]pyridazin-6-yl)-(3-pyrrolidin-1-ylpropyl)amine, used in the treatment or prophylaxis of disorders which are associated with overexpression or mutation of activin receptor-like kinases
04/26/2007US20070093489 Phthalazinone derivatives
04/26/2007US20070093488 Novel Benzothiazoles And The Use Thereof As Medicaments
04/26/2007US20070093487 Novel polycyclic compounds which modulate PPARgamma type receptors and cosmetic/pharmaceutical compositions comprised thereof
04/26/2007US20070093486 Enzyme-catalyzed dynamic kinetic resolution process for preparing (+)-(2s,3s)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinoland salts and solvates thereof
04/26/2007US20070093485 Substituted n-phenyl sulfonamide bradykinin antagonists
04/26/2007US20070093484 3-Substituted 5,6-diaryl-pyrazine-2-carboxamide and -2-sulfonamide derivatives as cb1 modulators
04/26/2007US20070093483 Use of derivatives of 2, 4-dihydro-[1,2,4] triazole-3-thione as inhibitors of the enzyme myeloperoxidase (mpo)
04/26/2007US20070093482 Thieno-imino acid derivatives for use as matrix metalloproteinase inhibitors
04/26/2007US20070093481 Benzopyran derivatives substituted with a thioxobenzoxazole derivative, pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containingthem
04/26/2007US20070093480 e.g. 2 {5,6-dimethoxy-1-[2-(4-methylpiperazin- 1 -yl)ethyl]-1H-indol-3 -yl}-1H-pyrrolo[2,3- b]pyridine; Insulin Growth Factor-1 (somatomedin) antagonist; antiproliferative, antitumor agent; solid tumor; prostate, lung and breast cancer
04/26/2007US20070093479 6-chloro-N-(3,3-dimethylbutyl)-5-phenyl-1H-indazol-3-amine; for treating neurodegenerative diseases such as Alzheimer's, fronto-parietal dementia, Pick's disease, Parkinson's disease, type II diabetes, corticobasal degeneration, in which phosphorylation of the tau protein is observed
04/26/2007US20070093478 Novel mycobacterial inhibitors
04/26/2007US20070093477 Alpha2C adrenoreceptor agonists
04/26/2007US20070093476 Novel compounds and their use in medicine,as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them
04/26/2007US20070093475 Short-acting benzodiazepines
04/26/2007US20070093474 Methods of modulating neurotrophin-mediated activity
04/26/2007US20070093473 7-Heteroarylsulfonyl-tetrahydro-3-benzazepine derivatives as antipsychotic agents
04/26/2007US20070093472 1-[(4-Ethynylphenyl)]-2-[(phenyl)]-pyrrolidine-1,2-dicarboxamide derivatives as inhibitors of coagulation factors xa and viia for the treatment of thromboses
04/26/2007US20070093471 Compositions and methods for the administration clozapine formulations which modulate body weight
04/26/2007US20070093470 LXR modulators
04/26/2007US20070093469 Substituted azetidine compounds as cyclooxygenase-1-cyclooxygenase-2 inhibitors, and their preparation and use as medicaments
04/26/2007US20070093468 Methods for treating disorders associated with hyperlipidemia in a mammal
04/26/2007US20070093467 2-(4-Chloro-5-methyl-3-trifluoromethyl-pyrazol-1-yl)-1-[4-(4-fluorobenzyl),4-hydroxypiperidin-1-yl]ethanone; potent chemokine receptor antagonists; antiinflammatory agents; immunotherapy; rheumatic diseases; antiarthritic agents; transplant rejection; multiple sclerosis
04/26/2007US20070093466 Neurotherapeutic treatment for sexual dysfunction
04/26/2007US20070093465 Cephem compound
04/26/2007US20070093464 chemical intermediates for making an oral antibiotics Sulbactam
04/26/2007US20070093463 Radiation enhancement agent for X-ray radiation therapy and boron neutron-capture therapy
04/26/2007US20070093462 Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients
04/26/2007US20070093461 Effect of Loteprednol etabonate on vascular dysfunction
04/26/2007US20070093460 Methods of using selective 11beta-HSD inhibitors to treat gluocorticoid associated states
04/26/2007US20070093459 Sustained release composition for cardio-, cerebro- and peripheral vascular diseases of a Vitamin D receptor activators, e.g., paricalcitol, calcitriol, doxercalciferol, and optionally an angiotensin converting enzyme inhibitor, an angiotensin II receptor I blocker, an aldosterone blocker; no side effect
04/26/2007US20070093458 Preparation of paricalcitol and crystalline forms thereof
04/26/2007US20070093457 Compositions for treatment of cancer and inflammation with curcumin and at least one nsaid
04/26/2007US20070093456 Derivatives of gambogic acid and analogs as activators of caspases and inducers of apoptosis
04/26/2007US20070093455 10-substituted tetracyclines and methods of use thereof
04/26/2007US20070093454 sodium channel modulators, such as Isobutyl 4-(6-(2-hydroxyphenyl)pyrimidin-4-yl)piperazine-1-carboxylate, used as analgesics
04/26/2007US20070093453 Sulfonamide-substituted chalcone derivatives and their use to treat diseases
04/26/2007US20070093452 Use of bivalent or polyvalent trisaccharides as fusion-inhibitors in all HIV types, subtypes, groups, strains, and circulating recombinant forms